Sionna Therapeutics, Inc. (SION) fair value: what the stock is really worth
As of Nov 19, 2026: fair value (intrinsic value) of Sionna Therapeutics, Inc. stock $3.26, price $2.97, upside +9.8%, quality 39 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Sionna Therapeutics, Inc.
SION · USThe stock is already about fairly priced and weak company.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.
How to read this chart
21‑month range $2.97 – $51.04 · fair‑value band $2.45 – $4.08 · the $2.97 price screens below the $3.26 fair value. As of Nov 14, 2026.
Every Wednesday you see whether Sionna Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Show moreShow less
The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Stock analysis
Sionna Therapeutics, Inc. (SION) currently trades at $2.97, while our estimate is $3.26, so the stock looks roughly fairly valued today (gap 8.9%).
Show more
Valuation
None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $2.45 (bear) to $4.08 (bull), the price of $2.97 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Sionna Therapeutics, Inc. reported revenue of $0 in FY2025 versus $0 in FY2022. Reported net income was −$75.3M in FY2025.
Key figures
Market cap $138M Micro · EPS (TTM) $-2.43 · Return on equity −39.0% · Return on assets (EBIT) −52.4% (4-year average) · Free cash flow −$66.7M · Net cash $49.8M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 94% below its 52-week high and at its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at 10%, SION screens cheaper than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, 5 officers or directors sold shares worth $40.5M and none bought.
- SaleRA CAPITAL MANAGEMENT, L.P.Director, 10% owner3,448,811 shares at $6.33$21.8MSep 17, 2026
- SaleOrbiMed Capital GP VIII LLCDirector4× since Dec 17, 2025: 152,102 shares, avg. $44.73$6.8MJul 7, 202610b5-1 plan
- SalePeter A. ThompsonDirector10× since Nov 24, 2025: 1,235,000 shares, avg. $45.08$55.7MJul 7, 202610b5-1 plan
- SaleJennifer FitzpatrickChief Legal Officer3× since Dec 5, 2025: 30,750 shares, avg. $39.33$1.2MJul 6, 202610b5-1 plan
- SaleORBIMED ADVISORS LLCDirector6× since Nov 24, 2025: 1,082,898 shares, avg. $45.13$48.9MJun 30, 202610b5-1 plan
- SaleJon Winkelried10% owner250,000 shares at $40.00$10.0MJan 22, 2026
- SalePeter KolchinskyDirector, 10% owner30,316 shares at $39.61$1.2MNov 21, 2025
Plus 5 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 19, 2026. All filings at the SEC ↗
Revenue & earnings trend
Watch SION, get fair value alerts →
Compare Sionna Therapeutics, Inc. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Dividend yield by industry
- EV/EBITDA by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $923.34 | $1,275.02 | +38% | vs SION |
| Vertex Pharmaceuticals Incorporated VRTX | $520.66 | $587.62 | +13% | vs SION |
| Samsung Biologics Co 207940 | ₩1,375,000 | ₩1,512,500 | +10% | vs SION |
| argenx SE ARGX | $942.04 | $908.40 | −4% | vs SION |
| CSL Limited CSL | A$197.29 | A$188.80 | −4% | vs SION |
| BeOne Medicines AG 6160 | HK$242.60 | HK$152.92 | −37% | vs SION |
| Moderna, Inc MRNA | $199.33 | $122.98 | −38% | vs SION |
| Revolution Medicines, Inc RVMD | $159.43 | $83.12 | −48% | vs SION |
| Celltrion, Inc 068270 | ₩215,000 | ₩74,574 | −65% | vs SION |
| Royalty Pharma plc RPRX | $67.72 | $19.01 | −72% | vs SION |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Sionna Therapeutics, Inc. (SION) overvalued or undervalued?
What is the fair value of SION?
What is the quality score of SION?
What is the price target for Sionna Therapeutics, Inc. (SION)?
What is the Sionna Therapeutics, Inc. stock forecast for 2026?
What is the intrinsic value of Sionna Therapeutics, Inc. (SION)?
Is Sionna Therapeutics, Inc. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of SION?
How much is Sionna Therapeutics, Inc. worth?
What do the bullish and bearish scenarios say about SION?
How solid is the balance sheet of Sionna Therapeutics, Inc. (SION)?
How far is SION from its 52-week high?
Which stocks are comparable to Sionna Therapeutics, Inc.?
Is Sionna Therapeutics, Inc. stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Sionna Therapeutics, Inc. (SION)?
What should I pay attention to with Sionna Therapeutics, Inc. right now?
Key figures of Sionna Therapeutics, Inc.
How large is the market capitalisation of Sionna Therapeutics, Inc. (SION)?
What are the earnings per share of Sionna Therapeutics, Inc. (SION)?
What is the return on equity of Sionna Therapeutics, Inc. (SION)?
What is the EBIT return on assets of Sionna Therapeutics, Inc. (SION)?
How much free cash flow does Sionna Therapeutics, Inc. (SION) generate?
How much net cash does Sionna Therapeutics, Inc. (SION) hold?
Watch Sionna Therapeutics, Inc. in the live analysis
One click puts Sionna Therapeutics, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.